Abivax
ABVX
165 hedge funds and large institutions have $4.41B invested in Abivax in 2025 Q3 according to their latest regulatory filings, with 130 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 8 closing their positions.
1,779% more capital invested
Capital invested by funds: $235M → $4.41B (+$4.17B)
1,525% more first-time investments, than exits
New positions opened: 130 | Existing positions closed: 8
320% more funds holding in top 10
Funds holding in top 10: 5 → 21 (+16)
284% more funds holding
Funds holding: 43 → 165 (+122)
47% more call options, than puts
Call options by funds: $5.49M | Put options by funds: $3.74M
20.44% more ownership
Funds ownership: 48.33% → 68.76% (+20%)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$263M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$194M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$169M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$95.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$105M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$70M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$56.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$52.4M |
| 5 |
VA
VR Adviser
New York
|
-$47.1M |
ABVX Hedge Fund Activity: Q3 2025 in Review
165 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q3 2025, worth a combined $4.41B — up 1,779% from $235M a quarter earlier.
Buyers outnumbered sellers: 130 funds opened new ABVX positions and 8 closed out — a net gain of 122 holders — while 16 added to existing stakes and 17 trimmed.
The largest buyer was UBS Group, adding an estimated $263M. The largest seller was ADAR1 Capital Management, cutting an estimated $105M.
- 165 institutional investors held Abivax (ABVX) as of Q3 2025, up from 43 in Q2 2025.
- Funds reported $4.41B of Abivax stock for Q3 2025, up 1,779% quarter-over-quarter.
- 130 funds opened new Abivax positions in Q3 2025 and 8 closed out, a net change of +122 holders.
- The largest Abivax buyer in Q3 2025 was UBS Group, an estimated $263M added.
- The largest Abivax seller in Q3 2025 was ADAR1 Capital Management, an estimated $105M sold.
Based on aggregated 13F filings for Q3 2025.